Neurocritical Care News

Prothena Corp. recently announced it would receive $80 million from Bristol Myers Squibb for an exclusive global license to an investigational therapeutic developed to address protein dysregulation.

The FDA has granted an expanded indication for BrainsWay’s Deep Transcranial Magnetic Stimulation system for depression treatment in patients aged 22 to 86 years, according to a company press release.

The FDA has selected an investigational AAV9 gene therapy for Rett syndrome to participate in a pilot program created to provide a boost to novel drug development for rare diseases, according to a release from the manufacturer.

DENVER — Subcutaneous administration of ocrelizumab showed similar safety and efficacy profiles to IV administration in multiple sclerosis at 24 weeks, according to David Jones, senior medical director at Genentech.

Annexon Biosciences has announced positive topline results from a phase 3, randomized placebo-controlled clinical trial examining an investigational monoclonal antibody in those with Guillain-Barré syndrome.

The FDA has granted regenerative medicine advanced therapy designation for an investigational gene therapy to treat Huntington’s disease, according to the manufacturer.

The European Commission has granted marketing authorization under exceptional circumstances for Qalsody to treat those with amyotrophic lateral sclerosis associated with a mutation in the superoxide dismutase 1 gene.

The Alzheimer’s Drug Discovery Foundation has invested $5 million in Coya Therapeutics to help accelerate development and advance drugs to prevent, treat and cure Alzheimer’s disease and related dementias.

DENVER — For the glymphatic system of the brain to function properly, individuals must pay attention to their sleep duration, regulation and deprivation, according to a presenter at the American Academy of Neurology annual meeting.

DENVER — Early initiation of treatment with ofatumumab showed sustained benefit to those with treatment-naïve relapsing multiple sclerosis, Gabriel Pardo, MD, said in this Healio video from the American Academy of Neurology annual meeting.